MX2023002995A - Uso de agonistas de lepr para el dolor. - Google Patents

Uso de agonistas de lepr para el dolor.

Info

Publication number
MX2023002995A
MX2023002995A MX2023002995A MX2023002995A MX2023002995A MX 2023002995 A MX2023002995 A MX 2023002995A MX 2023002995 A MX2023002995 A MX 2023002995A MX 2023002995 A MX2023002995 A MX 2023002995A MX 2023002995 A MX2023002995 A MX 2023002995A
Authority
MX
Mexico
Prior art keywords
pain
lepr
agonists
leptin
hypersensitization
Prior art date
Application number
MX2023002995A
Other languages
English (en)
Inventor
Elif Arioglu Oral
Baris Akinci
De Freitas Maria Cristina Foss
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023002995A publication Critical patent/MX2023002995A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos para reducir el dolor, el uso de opioides y la hospitalización en pacientes que padecen con una condición de deficiencia de leptina o resistencia a la leptina tal como lipodistrofia. Puede haber implicaciones de esta invención en otras formas de dolor crónico que implican la centralización o hipersensibilización del dolor por el sistema nervioso central.
MX2023002995A 2020-09-15 2021-09-15 Uso de agonistas de lepr para el dolor. MX2023002995A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078687P 2020-09-15 2020-09-15
PCT/US2021/050443 WO2022060827A2 (en) 2020-09-15 2021-09-15 Use of lepr agonists for pain

Publications (1)

Publication Number Publication Date
MX2023002995A true MX2023002995A (es) 2023-05-19

Family

ID=78080580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002995A MX2023002995A (es) 2020-09-15 2021-09-15 Uso de agonistas de lepr para el dolor.

Country Status (13)

Country Link
US (1) US20220098313A1 (es)
EP (1) EP4214232A2 (es)
JP (1) JP2023543409A (es)
KR (1) KR20230069969A (es)
CN (1) CN116670170A (es)
AU (1) AU2021343444A1 (es)
BR (1) BR112023004716A2 (es)
CA (1) CA3192156A1 (es)
CL (2) CL2023000727A1 (es)
IL (1) IL301252A (es)
MX (1) MX2023002995A (es)
PE (1) PE20231657A1 (es)
WO (1) WO2022060827A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
LU501817B1 (en) * 2022-04-07 2023-10-09 Univ Duisburg Essen Methods for treating mood disorders by administering a leptin receptor agonist
CN118986974A (zh) * 2024-08-22 2024-11-22 中国人民解放军陆军军医大学第二附属医院 4-(4-异噁唑)苯磺酰胺类化合物的新用途
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP2895513B1 (en) 2012-09-12 2018-05-23 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EA201991075A1 (ru) * 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
LT3773713T (lt) * 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija

Also Published As

Publication number Publication date
AU2021343444A9 (en) 2023-04-27
KR20230069969A (ko) 2023-05-19
BR112023004716A2 (pt) 2023-05-09
CA3192156A1 (en) 2022-03-24
CL2024001061A1 (es) 2024-10-18
AU2021343444A1 (en) 2023-04-20
WO2022060827A3 (en) 2022-04-28
JP2023543409A (ja) 2023-10-16
EP4214232A2 (en) 2023-07-26
CN116670170A (zh) 2023-08-29
US20220098313A1 (en) 2022-03-31
PE20231657A1 (es) 2023-10-17
WO2022060827A2 (en) 2022-03-24
CL2023000727A1 (es) 2023-11-17
IL301252A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
WO2022060827A3 (en) Use of lepr agonists for pain
EP4501952A3 (en) Conjugated hepcidin mimetics
PH12023500004A1 (en) Conjugated hepcidin mimetics
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
EA201890458A1 (ru) Композиции с усилителями проницаемости для доставки лекарств
EA201891142A1 (ru) Контроль клеточных окислительно-восстановительных уровней
EP4331679A3 (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4417252A3 (en) Cannabis based therapeutic and method of use
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
PH12022550510A1 (en) Conjugated hepcidin mimetics
WO2010129514A3 (en) Synergistic effects of blending multiple additives in uhmwpe
MX2015011408A (es) Antagonistas de il-33 y usos de estos.
WO2019209962A8 (en) Compounds and uses thereof
ATE532238T1 (de) Mehrfachbürste für schleifringe
BR112021017511A2 (pt) Codificação de áudio espacializada com interpolação e quantização de rotações
WO2019209948A8 (en) Compounds and uses thereof
WO2007103540A3 (en) Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ATE404206T1 (de) Orale suspension mit meloxicam
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
WO2020132378A3 (en) Compositions and methods of treatment for neurological disorders comprising depression
EP3817745A4 (en) PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION/DISPUTED COMPOUNDS AND METHODS OF USE
EP1476419A4 (en) N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE
BRPI0410857A (pt) método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
WO2021146487A3 (en) Il2 orthologs and methods of use